Chapter 5 ~ Infections
|
|
|
- Morris Flynn
- 5 years ago
- Views:
Transcription
1 Chapter 5 ~ Infections: Special Section 1 of 6 Chapter 5 ~ Infections Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233, and Surgical Prophylaxis Policy, Policy number 234 Notifiable diseases Doctors must notify the consultant in communicable disease control when attending a patient suspected of suffering from any of the diseases listed below: Anthrax Measles Rubella Cholera Meningitis Scarlet fever Diphtheria Meningococcal septicaemia Smallpox Dysentry (amoebic or bacillary) (without meningitis) Tetanus Encephalitis, acute Mumps Tuberculosis Food poisoning Ophthalmia neonatorum Typhoid fever Haemorrhagic fever (viral) Paratyphoid fever Typhus Hepatitis, viral Plague Whooping cough Leprosy Poliomyelitis, acute Yellow fever Leptospirosis Rabies Malaria Relapsing fever 5.1 Antibacterial drugs Penicillins Penicillinase-resistant penicillins TEMOCILLIN Injection 1g Non Policy Antibiotic Requires Broad-spectrum penicillins AMOXICILLIN Powder SF 3 g For ENT CO-AMOXICLAV Suspension SF 400/57 in Antipseudomonal penicillins PIPERACILLIN with tazobactam (TAZOCIN ) TICARCILLIN with clavulanic acid (TIMENTIN ) Injection 2g/250mg; 4g/500mg Injection 3g/200mg Cephalosporins and other beta-lactams CEFIXIME Suspension 100mg in Tablet 200 mg For use in Cystic Fibrosis For Obstetrics and Gynaecology For Obstetrics and Gynaecology CEFTAZIDIME Injection 500mg; 1g; 2g CEFTRIAXONE Injection 250mg; 1g CEFUROXIME Injection 250mg; 1.5g ERTAPENEM 1g 500mg/500mg IMIPENEM with Cilastatin MEROPENEM Injection 500mg; 1g Tetracyclines LYMECYCLINE Capsule 408mg (= For Dermatologist use 300mg tetracycline) MINOCYCLINE Modified release For Dermatologist use
2 Chapter 5 ~ Infections: Special Section 2 of 6 capsule 100mg Tablet 50mg; For Dermatologist use OXYTETRACYCLINE Tablet 250mg For Dermatologist use Tetracyclines (contd.) TIGECYCLINE 50mg Aminoglycosides AMIKACIN Injection 500mg in 2ml GENTAMICIN TOBRAMYCIN Intrathecal injection 5mg in 1ml Injection 40mg in 1ml; 80mg in 2ml Nebuliser solution 75mg/ml For use in Cystic Fibrosis Use in accordance with TA Macrolides AZITHROMYCIN Capsule 250mg For Obstetrics and Gynaecology For Paediatric use Clindamycin CLINDAMYCIN Suspension 200mg in Suspension 75mg in For Paediatric use Unlicensed Some other antibacterials CHLORAMPHENICOL Capsule 250mg COLISTIN SULPHOMETHATE SODIUM DAPTOMYCIN FUSIDIC ACID LINEZOLID Injection 1g (as sodium succinate) Injection 1 million units Powder for nebuliser solution 1 million units 350mg; 500mg Suspension 250mg in (= 175mg sodium fusidate) 600mg in 300ml Suspension 100mg in Tablet 600 mg For use in Cystic Fibrosis Use in accordance with NICE TA276 RIFAXIMIN Tablet 550mg On Gastroenterology advice and in SODIUM FUSIDATE 500mg Tablet 250mg SPECTINOMYCIN Injection 2g Unlicensed TEICOPLANIN Injection 200mg; 400mg accordance with NICE TA 337 Genito Urinary Medicine VANCOMYCIN Capsule 125mg Injection 500mg; 1g Sulphonamides and trimethoprim CO-TRIMOXAZOLE
3 Chapter 5 ~ Infections: Special Section 3 of 6 480mg in Suspension 240mg in ; 480mg in Tablet 480mg; SULFADIAZINE Injection 250mg in 1ml Tablet 500mg Antituberculous drugs RIFABUTIN Capsule 150mg Antileprotic drugs DAPSONE Tablet 50 mg For Dermatologist use Quinolones MOXIFLOXACIN Tablet 400mg NALIDIXIC ACID Tablet 500mg OFLOXACIN Tablet 200mg; 400mg 5.2 Antifungal drugs AMPHOTERICIN CASPOFUNGIN (Liposomal) 50mg 50mg; 70mg ITRACONAZOLE Capsule 100mg For Haematologist use Solution 50mg in. For Haematologist use. TERBINAFINE Tablet 250mg For Dermatologist use VORICONAZOLE Tablet 200mg For Haematologist use. 5.3 Antiviral drugs HIV infection Nucleoside reverse transcriptase inhibitors ABACAVIR Oral solution 100mg in ABACAVIR with lamivudine and zidovudine (TRIZIVIR ) DIDANOSINE Tablet 300mg Tablet 300mg abacavir / 150mg lamivudine / 300mg zidovudine Enteric coated capsule 250 mg; 400 mg EMTRICITABINE Capsule 200mg LAMIVUDINE Oral solution 50mg in Tablet 150mg Tablet 100mg For Chronic Hepatitis B Use in accordance with NICE (TA96) STAVUDINE Capsule 30mg; 40mg TENOFOVIR DISOPROXIL Tablet 245mg OR For chronic Hepatitis B, use in accordance with NICE (TA173) TENOFOVIR Tablet 245mg/100mg
4 Chapter 5 ~ Infections: Special Section 4 of 6 DISOPROXIL with Emtricitabine (TRUVADA ) ZIDOVUDINE Capsule 100mg; 250mg Injection 200mg in 20ml ZIDOVUDINE with lamivudine (COMBIVIR ) Oral solution 50mg in Tablet 300mg/150mg Protease inhibitors ATAZANAVIR Capsule 100mg; 150mg DARUNAVIR Tablet 300mg LOPINAVIR with ritonavir (KALETRA ) RITONAVIR SAQUINAVIR Capsule 133.3mg/33.3mg Film coated Tablet 200mg/50mg Oral solution 400mg/100mg in Oral solution SF 400mg in Soft capsule 100mg Tablet (Invirase ) 500mg Non-nucleoside reverse transcriptase inhibitors EFAVIRENZ Capsule 200mg NEVIRAPINE Herpesvirus infections Oral solution SF 150mg in Tablet 600mg Suspension 50mg in Tablet 200mg Herpes simplex and varicella-zoster infection FAMCICLOVIR Tablet 250mg For Ophthalmologist use Cytomegalovirus FOSCARNET SODIUM 6g in 1ml GANCICLOVIR 500mg VALGANCYCLOVIR Tablet 450mg Viral hepatitis Chronic Hepatitis B ENTECAVIR Tablet 500mcg, 1mg Oral Solution 50mcg/ml Use in accordance with NICE (TA153) ADEFOVIR DIPIVOXIL Tablet 10mg Use in accordance with NICE (TA96) Chronic Hepatitis C TELAPREVIR Tablet 375mg Use in accordance with NICE (TA252)
5 Chapter 5 ~ Infections: Special Section 5 of 6 BOCEPREVIR Capsule 200mg Use in accordance with NICE (TA253) SIMEPREVIR Capsule 150mg On Gastroenterology advice and in accordance with NICE TA 331 SOFOSBUVIR Tablet 400mg On Gastroenterology advice and in accordance with NICE TA Influenza OSELTAMIVIR ZANAMIVIR Capsule 30mg, 45mg, 75mg Oral Suspension 60mg in Powder for inhalation 5mg/blister Use in accordance with NICE (TA168) (TA158) Use in accordance with NICE (TA168) (TA158) Respiratory syncytial virus PALIVIZUMAB Injection 50mg; 100mg For Paediatric use RIBAVIRIN Tablet 200mg For Chronic Hepatitis C pegylated interferon, ribavirin and alfa interferon Use in accordance with NICE (TA75) For Hepatitis C peginterferon alfa and ribavirin) Use in accordance with NICE (TA200) Hepatitis C children and young people, peginterferon alfa and ribavirin Use in accordance with NICE (TA300) 5.4 Antiprotozoal drugs Antimalarials CHLOROQUINE PHOSPHATE (AVLOCHLOR ) CHLOROQUINE SULPHATE Tablet 250mg (=155mg chloroquine base) Syrup 68mg (= 50mg chloroquine base) in Tablet 200mg (= 150mg chloroquine base) MEFLOQUINE Tablet 250mg PRIMAQUINE Tablet 7.5mg Unlicensed Medicine PROGUANIL Tablet 100mg PROGUANIL Tablet 100mg/250mg HYDROCHLORIDE with atovaquone (MALARONE ) PYRIMETHAMINE Tablet 25mg PYRIMETHAMINE with sulfadoxine (FANSIDAR ) QUININE DIHYDROCHLORIDE RIAMET (artemether 20mg, lumefantrine 120mg) Tablet 25mg/500mg Injection 300mg in 1ml, 3000mg in 10ml Tablet Drugs for pneumocystis pneumonia PENTAMIDINE Injection 300mg Unlicensed Medicine
6 Chapter 5 ~ Infections: Special Section 6 of 6 ISETIONATE 5.5 Anthelmintics Nebuliser solution 300mg Unlicensed Medicine Schistosomicides PRAZIQUANTEL Tablet 500mg Unlicensed Medicine Drugs for stronyloidiasis ALBENDAZOLE Tablet 400mg Unlicensed Medicine IVERMECTIN Tablet 3mg; 6mg Unlicensed Medicine
5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
Report generated from BNF provided by FormularyComplete ( Accessed TA Number. Title Formulary Status Section
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACICLOVIR Aciclovir 5.3 Antiviral drugs->5.3.2
CEFACLOR Non Formulary 5.1 Antibacterial drugs->5.1.2 Cephalosporins, carbapenems, and other beta-lactams-> Cephalosporins
Report generated from BNF - Local Information provided by FormularyComplete (www.pharmpress.com). Accessed 31 07 2017 Title Formulary Status Section Amikacin Non Formulary 5.1 Antibacterial drugs->5.1.4
NHS Fife Antibiotic Guidance for the Treatment of Community Managed Infections
1 5. Infections Also see Primary Care and Hospital Antibiotic Guidance NHS Fife Antibiotic Guidance for the Treatment of Community Managed Infections Management of Serious Infections in Paediatrics. Guidance
Inventory of paediatric therapeutic needs
12 December 2012 EMA/PDCO/287222/2012 Human Medicines Development and Evaluation Infectious diseases Agreed by PDCO November 2012 Adopted by PDCO for release for consultation 7 December 2012 Start of public
Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing
Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing Infections therapeutic group PTAC and Subcommittee of PTAC minutes are
Both adult and pediatric* 24 (46% of 52 members) Region: New England 51 (48% of 107 members) 45 (52% of 87 members) 29 (47% of 62 members)
Infectious Diseases Society of America Emerging Infections Network Report for Query: Antimicrobial Drug Shortages 2016 Overall response rate: 701/1,597 (44%) physicians responded from 3/22/16 to 4/13/16.
CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines
Notifiable Infectious Diseases in Ireland 2001
Notifiable Infectious Diseases in Ireland 2001 Table 1. Annual number of infectious diseases notified in Ireland, 1982-2001 Infectious Disease 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993
1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017
To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea
B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α.
Pharmacology - Problem Drill 24: Antibiotics, Antifungal and Antiviral Drugs Question No. 1 of 10 1. reduces the replication of influenza A and B viruses by inhibiting viral neuraminidase. Question #01
gram neg.(semisynthetic) Bacteria Drugs that inhibit cell wall synthesis Drug Action Organisms Comments Spectrum of Action Mycobacterium
Mickey Dufilho s Drugs and Bugs Revised 10/10/15 Bacteria Drugs that Inhibit Cell Wall Synthesis Drug Action Spectrum of Action Comments Spectrum of Action Bacitracin Beta-Lactam antibiotics Penicillin
Chapter 5 Infections
Chapter 5 page number 1 Chapter 5 Infections First line drugs Drugs recommended in both primary and secondary care. Second line drugs Alternatives (often in specific conditions) in both primary and secondary
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,
1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016
To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical
APPENDIX: NATIONAL SURVEILLANCE DATA AND TRENDS
2008 Annual Surveillance Report Notifiable and Other s in New Zealand 49 APPENDIX: NATIONAL SURVEILLANCE DATA AND TRENDS COMPARISON OF NOTIFIABLE DISEASE CASES AND RATES FOR 2007 AND 2008 Table 37. Number
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active
The Medical Council of Hong Kong. Licensing Examination Part II - Proficiency Test in Medical English. Sample Test Paper.
The Medical Council of Hong Kong Licensing Examination Part II - Proficiency Test in Medical English Sample Test Paper Answer Book QUESTION I Circle the word TRUE or FALSE Note : One mark will be awarded
This letter authorises the extended use of the following guidance until 1st December 2018:
NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS NHS Grampian Date 29 1h May 2018 Our Ref FApenicillin/hype/MGPG/May 18 Enquiries to Frances Adamson Extension 56689 Direct Line 01224
Drug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD
Antimicrobial Dosing in Renal Insufficiency (Adults) ASP Handbook * In patients on hemodialysis (), give antimicrobial immediately after dialysis on dialysis days. = Intermittent hemodialysis = Peritoneal
Compendium of Notified Ceiling Prices NLEM 2015
Compendium of Notified Ceiling Prices NLEM 2015 The Compendium of Notified Ceiling Prices of Scheduled Drugs as per NLEM 2015 has been brought out with the objective of disseminating information related
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).
104 MMWR December 17, 2004
104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir
Invitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
Antiviral Chemotherapy
Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 37 1. NAME OF THE MEDICINAL PRODUCT Tablets* 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 600 mg efavirenz, 200 mg emtricitabine
FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary
At a Glance: VA ADAP Formulary Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Multi Class Combination Agents Protease Inhibitors
1. INTRODUCTION. 1.1 Standard Precautions
1. INTRODUCTION 1.1 Standard Precautions Standard precautions, originally known as universal precautions, are essential components in preventing the transmission of infectious diseases in the healthcare
Health Questionnaire
Health Questionnaire The information collected in this document is solely for the purpose of obtaining that which is required under the Ambulance Act of Ontario and is a condition of employment for all
Orientation Program for Infection Control Professionals
Orientation Program for Infection Control Professionals Module 7: Communicable Diseases Table of Contents Module 7: Communicable Diseases... 1 Objectives... 1 Instructions... 1 Overview... 2 Key Concepts...
Infectious Diseases Weekly Report. 12 January 2018 / Number 1. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 12 January / Number 1 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
DEPARTMENT OF DEFENSE AFHSB Reportable Events Monthly Report
DEPARTMENT OF DEFENSE AFHSB Reportable Events Monthly Report July 2016 Report Description Reportable Events among all beneficiaries received from the Services over the past 5 years are used to create ranges
DEPARTMENT OF DEFENSE AFHSB Reportable Events Monthly Report
DEPARTMENT OF DEFENSE AFHSB Reportable Events Monthly Report May 2016 Report Description Reportable Events among all beneficiaries received from the Services over the past 5 years are used to create ranges
THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
Infectious Diseases Weekly Report. 23 August 2018 / Number 33. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 23 August / Number 33 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
Infectious Diseases Weekly Report. 8 November 2018 / Number 44. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 8 November / Number 44 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
Infectious Diseases Weekly Report. 15 November 2018 / Number 45. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 15 November / Number 45 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
Infectious Diseases Weekly Report. 14 March 2019 / Number 10. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 14 March / Number 10 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
Infectious Diseases Weekly Report. 22 March 2019 / Number 11. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 22 March / Number 11 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
Infectious Diseases Weekly Report. 28 March 2019 / Number 12. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 28 March / Number 12 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
Infectious Diseases Weekly Report. 4 April 2019 / Number 13. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 4 April / Number 13 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
Infectious Diseases Weekly Report. 11 April 2019 / Number 14. The infectious diseases which all physicians must report
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 11 April / Number 14 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
Antiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
Malaria prevention: source = The Sanford Guide to Antimicrobial Therapy. Gilbert et al.
Malaria prevention: Agent Adult dose a Contraindications Application Notes Atovaquoneproguanil 250/100mg x1/day Insufficient data in pregnancy Prophylaxis for areas with CQ resistance, 2 expensive with
Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.
AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough
Infectious Diseases Weekly Report. 14 March 2013 / Number 10
Infectious Diseases Weekly Report TOKYOIDWR Tokyo Metropolitan Infectious Disease Surveillance Center 14 March / Number 10 Surveillance System in Tokyo, Japan The infectious diseases which all physicians
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 36 1. NAME OF THE MEDICINAL PRODUCT mg/300 mg Tablets* 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 600 mg efavirenz, 200 mg
MONTEFIORE MEDICAL CENTER
DEPARTMENT OF PHARMACY MONTEFIORE MEDICAL CENTER SUBJECT: MANUAL CODE: Restricted Drugs Policy, Antibiotic Restriction PH-R-5 DATE ISSUED: August, 1976 DATE REVISED: September 2000, October 2003, September
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
Drug Treatment Program Update
Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
2019 PHP PRIMARY CARE INCENTIVE
Primary Care Physicians (PCP) of Physicians Health Network (PHN) may be eligible for an incentive payment in accordance with this PHP PCP Incentive (hereinafter referred to as the PCP Incentive ). As described
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 36 1. NAME OF THE MEDICINAL PRODUCT mg/300 mg Tablets* 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 600 mg efavirenz, 200 mg
The Communicable Disease Control Regulations
COMMUNICABLE DISEASE CONTROL 1 The Communicable Disease Control Regulations Repealed by Chapter P-37.1 Reg 11 (effective April 17, 2003). Formerly Chapter P-37.1 Reg 4 (effective January 1, 1997). NOTE:
Validation of communicable disease reporting from hospitals using the hospital discharge database, Arizona,
Validation of communicable disease reporting from hospitals using the hospital discharge database, Arizona, 2007 2009 (Poster is shared here as an 8.5 x11 document for easier viewing. All content is identical.)
Antiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August
Antiviral Agents Dr. Yunita Sari Pane, MS DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU 06 August 2009 1 VIRUSES Obligate intracellular parasites Consist of a core genome in a protein shell and some are surrounded
WHO Model List of Essential Medicines
WHO Model List of Essential Medicines 20th List (March 2017) (Amended August 2017) Status of this document This is a reprint of the text on the WHO Medicines website http://www.who.int/medicines/publications/essentialmedicines/en/
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 34 1. NAME OF THE MEDICINAL PRODUCT AVIRODAY-EM * 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 600 mg efavirenz, 200 mg emtricitabine
Communicable Disease Report January 2019
Licking County Health Department Communicable Disease Report January This report contains information regarding suspected, probable, and confirmed cases of the diseases listed and are subject to change
Chapter 49. Antiviral Agents
Chapter 49 Antiviral Agents Antiviral Drugs 1. Characters of Virus Viruses are obligate intracellular parasites their replication depends primarily on synthetic processes of the host cell. 2.Classification
HEALTH REQUIREMENTS AND SERVICES: FFAD COMMUNICABLE DISEASES (EXHIBIT) REQUIREMENTS FOR EXCLUDING STUDENTS AND REPORTING CONDITIONS
REQUIREMENTS FOR EXCLUDING STUDENTS AND REPORTING CONDITIONS The information on the chart below has been collected from Department of Health rules at 25 TAC 97.3, 97.6, 97.7, and 97.132 The major criterion
I is a cascading prodrug. II is used to treat hepatitis B infection III ultimately inhibits viral reverse transcriptase.
Medicinal Chemistry 410 Exam #1 February 19, 2010 ame: Med. Chem. # 1 Part. (75 Points) There are 50 multiple choice questions worth 1.5 points each (75 Points). Please use the cantron heet provided. f
Thank you for your request for information that has been processed under reference number
Corporate Development Contact us: dhft.foi@nhs.net Royal Derby Hospital Uttoxeter Road Derby DE22 3NE Tel: 01332 265500 Minicom: 01332 785566 www.derbyhospitals@nhs.uk Follow us on Twitter @DerbyHospitals
Infectious Disease Hot Topics: 2008
Infectious Disease Hot Topics: 2008 Joseph Domachowske MD Professor of Pediatrics, Microbiology and Immunology Golisano Children s Hospital at SUNY Upstate Medical University Topic 1: COMMUNITY-ASSOCIATED
LRI Children s Hospital
Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval
Statistical Appendix. List of tables
Statistical Appendix List of tables A1 Sociodemographic summary: by locality/chp A2 Estimated population: by age group and locality/chp A3 Projected population: by age group and sex A4 Births: by year
FINAL. Etiologic Agents & Related Information to Know. Chapter 21: Microbial Diseases of Skin and Eyes Page No. Know term "diphtheroids"...
10 th Edition Tortora FINAL Microbiology Etiologic Agents & Related Information to Know Chapter 21: Microbial Diseases of Skin and Eyes Know term "diphtheroids"................. 586 Agents of boils and
Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016
Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology
MANITOULIN-SUDBURY DSB
MANITOULIN-SUDBURY DSB Pre-Employment Package Paramedic Hire Manitoulin-Sudbury District Services Board 2019 To be considered for Paramedic recruitment this pre employment package must be fully completed
Year 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 9 A 37 year old man with known human immunodeficiency virus (HIV) infection for 10 years presents with severe renal colic for which he has no prior
Appendix 4: Renal impairment
Appendix 4: Renal impairment Reduced renal function may cause problems with drug therapy for the following reasons: 1. The failure to excrete a drug or its metabolites may produce toxicity. 2. The to some
Surveillance of Infection and Data Collection
Infection Prevention and Control Assurance - Standard Operating Procedure 3 (IPC SOP 3) Surveillance of Infection and Data Collection Why we have a procedure? Adherence to this procedure will ensure the
Lester A. Deniega M.D. Associate Professor Department of Pediatrics FPPS, FPIDSP
Highlights in Pediatric Infectious Diseases Lester A. Deniega M.D. Associate Professor UST Department of Pediatrics FPPS, FPIDSP The 29 Antimic crobial Resistance Surveillance Pro ogram Progress Rep port
- They come in all sizes. -- General Structure is similar.
- They come in all sizes. -- General Structure is similar. Centers for Disease Control (CDC) and Prevention. Influenza Prevention and Control. Influenza. Available at: http://www.cdc.gov/ncidod/diseases/flu/fluinfo.htm.
Present State and Measures against Infectious Diseases in Tokyo
Asian Network of Major Cities 21 Asian Infectious Disease Project Present State and Measures against Infectious Diseases in History of Law on Infectious Diseases Revisions 1897 1999 23 Communicable Disease
PRINCIPLES OF PREVENTION AND CONTROL OF INFECTIOUS DISEASES Concepts Prevention measures taken to healthy individuals before the onset of diseases.
PRINCIPLES OF PREVENTION AND CONTROL OF INFECTIOUS DISEASES Concepts Prevention measures taken to healthy individuals before the onset of diseases. Control (secondary prevention) measures taken after occurrence
Statistical Appendix. Annual Report document. Public Health 2016/17
Statistical Appendix List of tables A1 Sociodemographic summary: by locality/hscp A2 Estimated population: by age group and locality/hscp A3 Projected population: by age group and sex A4 Births: by year
DHHS 2124 (Revised 7/03) EPIDEMIOLOGY. Hemorrhagic Fever (68)] Causative Organism: [Encephalitis, arboviral (9), Other Foodborne Disease (13), Viral
![DHHS 2124 (Revised 7/03) EPIDEMIOLOGY. Hemorrhagic Fever (68)] Causative Organism: [Encephalitis, arboviral (9), Other Foodborne Disease (13), Viral](/thumbs/85/91700736.jpg "DHHS 2124 (Revised 7/03) EPIDEMIOLOGY. Hemorrhagic Fever (68)] Causative Organism: [Encephalitis, arboviral (9), Other Foodborne Disease (13), Viral")
Reporters should indicate in the "COMMENTS" section the source of infection, if known, particularly for foodborne diseases. This area of the card is used by State or local health department staff to identify
Flu adenovirus h1n1 h3n2 h5n1 ah1n1
Influenza influenza Flu adenovirus h1n1 h3n2 h5n1 ah1n1 Gastroenteritis Gastroenteritis stomach flu gastroenteritides gastroenterities food poisoning campylobacter colitis gastroenterocolitis gastrointestinal
Dry injection list 1-Ceftriaxone 1000 mg & Sulbactam 500 mg Inj. 2-Ceftriaxone 500 mg & Sulbactam 250 mg Inj.
Dry injection list 1-Ceftriaxone 1000 mg & Sulbactam 500 mg Inj. 2-Ceftriaxone 500 mg & Sulbactam 250 mg Inj. 3-Ceftriaxone 250mg & Sulbactam 125mg Inj. 4-Ceftriaxone 125mg & Sulbactam 62.5mg Inj. 5-Rabeprazole
Antiviral Drugs. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
Antiviral Drugs Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Viruses Viruses are the smallest infective agents, consisting of nucleic acid (DNA or RNA) enclosed
Cholera. Cholera prevention and control. Mode of Transmission. Ganges River Delta. Public health significance
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Cholera prevention
Recommended exclusion periods for childhood infections
Childhood Infections: Recommended exclusion periods for childhood infections DISEASE INCUBATION PERIOD EXCLUSION PERIOD OF EXCLUSION OF PERIOD WHEN INFECTED PERSON CONTACTS INFECTIOUS Athletes Foot Unknown
Infectious Disease Surveillance System in Korea. Byungguk Yang Korea Centers for Disease Control and Prevention
Infectious Disease Surveillance System in Korea Byungguk Yang Korea Centers for Disease Control and Prevention 1 General information About Korea About KCDC (Korea Centers for Disease Control and Prevention)
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 39, 2018 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 33, 2018 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 50, 2018 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 49, 2018 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 22, 2018 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 3, 2019 (Notification
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 38, 2018 (Notification
Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
Antimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
Exclusion Periods for Infectious Diseases
Exclusion Periods for Infectious Diseases Amoebiasis (Entamoeba Histolytica) Campylobacter Candidiasis Chickenpox (Varicella) CMV (Cytomegalovirus Infection) Conjunctivitis Cryptosporidium Infection Diarrhoea
LIST OF APPENDICES. Appendix B Ontario Regulation 558/91 Specification of Communicable Diseases
LIST OF APPENDICES Appendix A Ontario Regulation 199/03 Control of West Nile Virus Appendix B Ontario Regulation 558/91 Specification of Communicable Diseases Appendix C Ontario Regulation 559/91 Specification
NJDOH-approved confirmed NJDOH-approved confirmed AND probable
Technical Notes for January 3, 2016 December 31, 2016 New Jersey Reportable Communicable Disease Summary Report (excludes sexually transmitted diseases [chancroid, chlamydia, granuloma inguinale, gonorrhea,
Reporting of Communicable Diseases
Purpose Audience Policy To establish a system for reporting communicable diseases that are of public health importance to County Health Departments as required by state law. Infection preventionists, physicians,